The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).
T. D. Bachelot
Consultant or Advisory Role - GlaxoSmithKline (U)
Research Funding - GlaxoSmithKline
G. Romieu
No relevant relationships to disclose
M. Campone
No relevant relationships to disclose
V. Dieras
Consultant or Advisory Role - GlaxoSmithKline (U)
Research Funding - GlaxoSmithKline
C. Cropet
No relevant relationships to disclose
H. H. Roche
No relevant relationships to disclose
M. Jimenez
Research Funding - GlaxoSmithKline
E. Le Rhun
No relevant relationships to disclose
J. Pierga
No relevant relationships to disclose
A. Gonçalves
No relevant relationships to disclose
M. Leheurteur
No relevant relationships to disclose
J. Domont
No relevant relationships to disclose
M. Gutierrez
No relevant relationships to disclose
H. Cure
No relevant relationships to disclose
J. Ferrero
No relevant relationships to disclose
C. Labbe
No relevant relationships to disclose